Print Page     Close Window     

Press Releases

Seres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Tuesday, January 31, 2017 at 8:00 a.m. ET to discuss the results of its in-depth analyses of the previously reported SER-109 Phase 2 clinical study in patients with multiply recurrent C. difficile infection.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 62194071. To join the live webcast and access slides to accompany the conference call, please visit the “Investors and Media” section of the Seres website at

A webcast replay and the accompanying slides will be available on the Seres website beginning approximately two hours after the event and will be archived for 30 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. The Phase 2 study of Seres’ program SER-109 has been completed in multiply recurrent C. difficile infection. Seres’ second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit Follow us on Twitter @SeresTx.

Source: Seres Therapeutics, Inc.

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications

© Seres Therapeutics. All Rights Reserved.